Overview

Angiotensin II in Liver Transplantation

Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of Angiotensin II as a second-line vasopressor (drug that raises the blood pressure) during liver transplantation.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
La Jolla Pharmaceutical Company
Treatments:
Angiotensin II
Angiotensinogen
Giapreza